Form 4 Filing for Michael O'Grady at Abbott Laboratories

This filing details transactions made by Michael O'Grady, a director at Abbott Laboratories, on April 24, 2026. O'Grady was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. These RSUs will be settled in common shares on a one-to-one basis upon separation from service, death, or a change in control. Additionally, O'Grady received an option to purchase 5,929 common shares, with an exercise price of $91.86, expiring on April 23, 2036. This transaction is exempt from Section 16 under Rule 16b-3. The filing also includes a Power of Attorney document authorizing specific individuals to act on O'Grady's behalf for SEC filings.